In this study, we describe a 2-year-old boy patient with nephroblastoma who has developed toxic epidermal necrolysis (TEN) associated with the combination chemotherapy administration of dactinomycin and vincristine. A skin biopsy confirmed the diagnosis of TEN, and with methylprednisolone pulse therapy, intravenous immunoglobulin (IVIG), and supportive care, the patient improved significantly.
In this study, we describe a 2-year-old boy patient with nephroblastoma who has developed toxic epidermal necrolysis (TEN) associated with the combination chemotherapy administration of dactinomycin and vincristine. A skin biopsy confirmed the diagnosis of TEN, and with methylprednisolone pulse therapy, intravenous immunoglobulin (IVIG), and supportive care, the patient improved significantly.
Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a rare, acute, and life-threatening mucocutaneous spectrum disease characterized by extensive, full-thickness epidermal necrosis and sloughing of the skin and the mucosal surface of the oral cavity, gut, kidney, eye, genitalia, and/or lung. According to the severity and extent of widespread epidermal detachment, SJS/TEN is classified as SJS, SJS/TEN overlap, and TEN with less than 10%, 10%-30%, and 30% of body surface area, respectively. The majority of cases of SJS/TEN are the results of a hypersensitive reaction to a drug, and the drugs most commonly associated with the diseases are anticonvulsants, sulfa preparations, antibiotics, nonsteroidal anti-inflammatory drugs, allopurinol and antiretroviral drugs, etc. (Chung et al., 2016) . In addition to drugs, other precipitating factors include the infection-, malignancy-, collagen-, and vascular-related factors. The study of Hockett (2004) is very nonspecific regarding the types of malignancies connected with SJS and TEN, but this association may be related to the drugs used to treat specific malignancies or their side effects. In addition, there remain approximately 20% of SJS/TEN cases without an identified cause (Schwartz et al., 2013; Chung et al., 2016) .
A 2-year-old boy was admitted to the Department of Urological Surgery, Beijing Children's Hospital, Capital Medical University, Beijing, China, with an abdominal mass that ultrasound and computed tomography examination revealed as a left kidney nephroblastoma (size 15.8 cm×14.5 cm×12.4 cm) with pulmonary and osseous metastases, and the patient received combination chemotherapy with dactinomycin (Cosmegen; 15 μg/(kg·d) intravenously in the first 5 d) and vincristine (1.5 mg/(m 2 ·d) intravenously once per week). After one week, he developed multiple morbilliform rashes initially over limbs, then chest, with high fever, and his rash quickly progressed into a widespread confluent erythematous and necrosis eruption with blistering (Figs. 1a and 2b), painful oral erosions and conjunctivitis (Fig. 1c) .
The patient was clinically diagnosed as TEN by a dermatology consultation. A skin biopsy showed loss of epidermis secondary to full thickness necrosis, with mild chronic inflammation noted in the dermoepidermal junction and upper dermis (Fig. 2) . These findings were consistent with TEN. Dactinomycin and vincristine were immediately discontinued and the patient was started on IVIG 1.0 g/kg body weight per day infused and methylprednisolone pulse therapy (20 mg/kg body weight) for 3 successive days. care, temperature management, and pain control. By Day 11 his temperature was normal; by Day 13 the rash was not deteriorating and the dosage of methylpredinisolone began to reduce gradually. On Day 20, there was quite a resolution of the rash, and almost healing of the oral mucous. All dermal and mucosal lesions have healed without scarring after 23 d. Then other regimen chemotherapy was initiated.
The results of laboratory tests including complete blood counts, electrolytes, kidney function, and liver function were nearly normal. The infectious workup including blood cultures, mycoplasma pneumoniae, herpes simplex virus, Epstein Barr virus, cytomegalovirus, and coxsackievirus was done, and the results were negative.
Identification and prompt removal of precipitating factors are the most pivotal and important steps for the lifesaving management of TEN. In our case, we believed that the patient problem was related to one of two chemotherapy drugs because no convincing alternative explanation such as other suspected drug or infection was proposed. In addition, the syndrome was not present before the initiation of chemotherapy, suggesting that it was not part of the presenting features of his nephroblastoma. In this case, dactinomycin was more suspected as the offending drug than vincristine, because SJS/TEN has been reported with dactinomycin use in postmarketing surveillance (http://www.rxlist.com/cosmegen-drug.htm), while vincristine is not commonly associated with skin reactions. Moreover, the patient was started on other regimen chemotherapy, which included vincristine, and this regimen did not cause any rashes. Although TEN occurs in a very small percentage of patients who use chemotherapy drugs, several reports have described SJS/TEN induced by other anticancer agents such as methotrexate, procarbazine, gemcitabine, cisplatin, and 5-FU (Yang et al., 2000; Jones et al., 2006; Yoshifuku et al., 2015; Aznab and Khazaei, 2016) . Malignancy is known to be associated with an increased mortality rate in patients with TEN. Therefore, except for antineoplastic drugs, we should also consider the link between malignancies themselves and SJS/TEN. There were two case reports on SJS associated with Hodgkin's disease, which illustrated the rare association of SJS revealing Hodgkin's disease and postulated that the link between both diseases may be a paraneoplastic syndrome induced by granulysin secretion by tumor cells, a mediator responsible for damage to keratinocytes (Schoeffler et al., 2014) . Gravante et al. (2007) suggested that oncologic diseases were the most frequent comorbidities in their SJS/TEN case series; Wu et al. (2015) found that for specific cancer types (hepatocellular carcinoma and colorectal cancer), chemotherapy and malnutrition may contribute to poor prognosis in patients with malignancies developing SJS/TEN.
In conclusion, it is very critical but complicated to identify the offending agents when oncologic patients develop SJS/TEN during chemotherapy. Apart from identification of suspected culprit drugs including chemotherapy agents, concurrent multi-drug regimens such as anticonvulsants, antibiotics, antivirals, or nonsteroidal anti-inflammatory drugs, influences of malignancies on occurrence and prognosis of SJS/TEN should be considered. Early recognition and intervention can significantly alter the course of the disease and improve the outcome. This case has served as an alert that the oncologist must be aware in his/her clinical practice of this particular syndrome and should be able to observe patients closely for potentially dangerous cutaneous reaction and treat it as an oncologic emergency. Also the dermatologist must be alert to the possibility of the development of SJS/TEN in oncologic patients with chemotherapy. As soon as the first suspicious sign is observed, they need to make a correct diagnosis, discontinue culprit drugs immediately, and initiate aggressive medical management or refer to appropriate centers promptly.
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